The Personalized Medicine Biomarkers Market Size is valued at USD 22.9 Bn in 2023 and is predicted to reach USD 59.1 Bn by the year 2031 at an 12.8% CAGR during the forecast period for 2024-2031.
The Personalized Medicine Biomarkers Market is a continuously developing area of healthcare focused on using biomarkers, which are biological markers such as proteins or genetic mutations for individualized treatments. Thus, these biomarkers are useful in all the stages involved in healthcare, starting from preliminary detection of the disease till proper diagnosis, selection of treatment, and monitoring. This approach is aligned with the patient's unique biological profile and, therefore, increases the therapeutic outcomes while minimizing the potential side effects in fields such as oncology, cardiology, and autoimmune diseases.
The key drivers of this market are the increasing incidence of chronic diseases such as cancer, cardiovascular conditions, and diabetes that require more accurate diagnostic and therapeutic solutions. Further, advancements in genomics and proteomics are accelerating the discovery and application of new biomarkers, increasing our understanding of disease mechanisms. These are also revolutionizing drug development, with the identification of appropriate candidates for clinical trials and improved stratification of patients for targeted therapies.
The personalized medicine biomarkers market is segmented by type, application, end user. By type the market is segmented into genetic biomarkers, protein biomarkers, metabolite biomarkers. By application the market is categorized into oncology, neurology, diabetes, autoimmune diseases, cardiology, and others. By end user the market is categorized into hospitals, diagnostic laboratories, research institutions.
The genetic biomarkers segment is a key driver of the Personalized Medicine Biomarkers Market, particularly in oncology, would be the genetic biomarkers segment where their value lies in finding the appropriate specific tumor mutations so that specific targeted therapies might be available for an individual patient for better treatment. The genomics technologies now include advancements in next-generation sequencing that have improved in the discovery of genetic mutations better for predictions related to disease susceptibility and regarding treatment responses. Further regulatory support for companion diagnostics based on genetic biomarkers spurs innovation and drives investment by pharmaceutical companies, fueling the growth of the market.
The Oncology segment is the fastest-growing application area in the Personalized Medicine Biomarkers Market, led by the increasing prevalence of cancer and the growing demand for biomarkers that predict patient responses to targeted therapies and immunotherapies. Cancer cases are expected to rise to 29.5 million by 2040, and the need for accurate diagnostic and therapeutic solutions is growing. Improvements in genomic technologies, including NGS, have transformed cancer diagnostics by allowing the precise determination of genetic mutations that indicate targeted therapy. Moreover, regulatory support from agencies, such as the FDA, which has approved many targeted cancer therapies, continues to further drive investment in biomarker R&D, which further establishes oncology's leadership.
North America is an influential region for the Personalized Medicine Biomarkers Market, mainly due to the presence of big names such as Thermo Fisher Scientific, Illumina, and Guardant Health, leaders in biotechnology that innovate research and development for biomarkers. Advanced healthcare infrastructure in the region along with the latest technologies, such as NGS and liquid biopsies, optimize biomarker identification and personalized treatment. Advances in genomic technologies are also underpinned by the rise in the demand for targeted therapies in the wake of rising chronic disease incidence, especially cancer. Substantial research funding in North America also ensures that collaborations among academic institutions and industry players create a great momentum for personalizing medicines.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 22.9 Bn |
| Revenue Forecast In 2031 | USD 59.1 Bn |
| Growth Rate CAGR | CAGR of 12.8% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Application, End User, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Foundation Medicine, Inc., Genomic Health, Inc, Guardant Health, Inc., Illumina, Inc., Luminex Corporation, Merck KGaA, Myriad Genetics, Inc, QIAGEN N.V, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., Coriell Life Sciences, Laboratory Corporation of America Holding, NeoGenomics Laboratories, Quest Diagnostics Incorporated |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Personalized Medicine Biomarkers Market by Type -
Personalized Medicine Biomarkers Market by Application -
Personalized Medicine Biomarkers Market by End User -
Personalized Medicine Biomarkers Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Personalized Medicine Biomarkers Market Snapshot
Chapter 4. Global Personalized Medicine Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Personalized Medicine Biomarkers Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Personalized Medicine Biomarkers Industry Trends
Chapter 5. Personalized Medicine Biomarkers Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. Market Share by Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type:
5.2.1. Genetic Biomarkers
5.2.2. Protein Biomarkers
5.2.3. Metabolite Biomarkers
Chapter 6. Personalized Medicine Biomarkers Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
6.2.1. Oncology
6.2.2. Neurology
6.2.3. Diabetes
6.2.4. Autoimmune Diseases
6.2.5. Cardiology
6.2.6. Others
Chapter 7. Personalized Medicine Biomarkers Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
7.2.1. Hospitals
7.2.2. Diagnostic Laboratories
7.2.3. Research Institutions
Chapter 8. Personalized Medicine Biomarkers Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Personalized Medicine Biomarkers Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.2.3. North America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.2.4. North America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
8.3. Europe
8.3.1. Europe Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.3.3. Europe Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.3.4. Europe Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.4.3. Asia Pacific Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts By Application, 2019-2031
8.4.4. Asia Pacific Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
8.5. Latin America
8.5.1. Latin America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.5.3. Latin America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.5.4. Latin America Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
8.6.3. Middle East & Africa Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
8.6.4. Middle East & Africa Personalized Medicine Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Agilent Technologies, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Bio-Rad Laboratories, Inc.
9.2.3. Foundation Medicine, Inc.
9.2.4. Genomic Health, Inc
9.2.5. Guardant Health, Inc.
9.2.6. Illumina, Inc.
9.2.7. Luminex Corporation
9.2.8. Merck KGaA
9.2.9. Myriad Genetics, Inc
9.2.10. QIAGEN N.V
9.2.11. Roche Diagnostics
9.2.12. Siemens Healthineers
9.2.13. Thermo Fisher Scientific Inc.
9.2.14. Coriell Life Sciences.
9.2.15. Laboratory Corporation of America Holding
9.2.16. NeoGenomics Laboratories
9.2.17. Quest Diagnostics Incorporated
9.2.18. Other Prominent Players
Personalized Medicine Biomarkers Market by Type -
Personalized Medicine Biomarkers Market by Application -
Personalized Medicine Biomarkers Market by End User -
Personalized Medicine Biomarkers Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-